BILLERICA, Mass., July 17, 2019 /PRNewswire/ -- Bruker Corporation
(Nasdaq: BRKR) has been advised that former board member, Mr.
Joerg C. Laukien, has authorized a
block sale of Bruker shares as part of his retirement planning and
portfolio diversification. Joerg
Laukien retired from the Bruker board of directors effective
November 5, 2018. He is the brother
of Bruker's President and CEO Frank H.
Laukien, who is not selling any shares in this
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries and
develop new applications that improve the quality of human life.
Bruker's high-performance scientific instruments and high-value
analytical and diagnostic solutions enable scientists to explore
life and materials at molecular, cellular and microscopic levels.
In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular research, in applied and pharma applications, in
microscopy and nanoanalysis, and in industrial applications, as
well as in cell biology, preclinical imaging, clinical phenomics
and proteomics research and clinical microbiology. For more
information, please visit: www.bruker.com.
Director, Investor Relations & Corporate Development
T: +1 (978) 663 – 3660, ext. 1479
View original content to download
SOURCE Bruker Corporation